1. Looking Back, Looking Forward

   • Kenneth I. Kaitin

   From the Editor-In-Chief 30 December 2004 Pages: 313 - 314

2. Social Pharmacology: Integrating Pharmaceutical and Social Science Research on Drug Effects

   • Michael Montagne

   Clinical and Nonclinical Drug Development 30 December 2004 Pages: 315 - 320

3. Social Pharmacology: Conceptual Remarks

   • José-Luis Alloza

   Clinical and Nonclinical Drug Development 30 December 2004 Pages: 321 - 329

4. Barriers to Adherence in Elderly Heart Failure Patients

   • Carol J. Hope
   • Jingwei Wu
   • Michael D. Murray

   Clinical and Nonclinical Drug Development 30 December 2004 Pages: 331 - 341

5. Assessing the Relationship between Investigator Global Evaluation and Acne Lesion Counts

   • Mohamed Alosh
   • Jonathan Wilkin

   Clinical and Nonclinical Drug Development 30 December 2004 Pages: 343 - 351

6. The Problem of Readability of Informed Consent Documents for Clinical Trials of Investigational Drugs and Devices: United States Considerations

   • S. Michael Sharp

   Clinical and Nonclinical Drug Development 30 December 2004 Pages: 353 - 359

7. Basing Intention-to-Treat on Cause and Effect Criteria

   • William H. Stewart

   Statistics 30 December 2004 Pages: 361 - 369

8. Statistical Issues in Clinical Trial Data Audit

   • Paul Zhang

   Statistics 30 December 2004 Pages: 371 - 386

9. Unequal Center Sizes, Sample Size, and Power in Multicenter Clinical Trials

   • Francis Ruvuna

   Statistics 30 December 2004 Pages: 387 - 394

10. Quality Assurance Practices for Pharmaceutical Industry-Based Drug Information Departments: A Review and Case Study

    • Stacey M. Fung
    • Joyce Serrano Martin

    Drug Information 30 December 2004 Pages: 395 - 405

11. Primary Care Practitioners’ Uptake of a Secondary Care-Based Medicines Information Service in the United Kingdom

    • Jill Rutter
    • David Brown
    • Paul Rutter

    Drug Information 30 December 2004 Pages: 407 - 416